Azurity Pharmaceuticals has announced the purchase of Eton Pharmaceuticals’ neurology portfolio.
These products include lamotrigine (ET-105), zonisamide (ET-104), and topiramate (ET-101). According to Azurity, these medications are currently under review with the US Food and Drug Administration (FDA) as new drug applications.
“Many patients have needs that are not sufficiently addressed by existing medications. Azurity aims to solve for these gaps by developing new alternatives that may benefit patients,” said Amit Patel, chairman and CEO of Azurity Pharmaceuticals, New York, USA.
According to the company, these products augment Azurity’s existing portfolio of other products within this new therapeutic area of neurology. Azurity further state it is committed to deepening and broadening its therapeutic area and dosage form coverage to expand opportunities for specialised patient care.
